Piramal Critical Care Monday said it has launched in the US Morphine Sulfate injection with Mitigo trademark used for treatment of intractable chronic pain.
The injection has been launched in 10 mg/ml and 25 mg/ml concentrations, Piramal Critical Care said in a statement.
"We are pleased to support intrathecal therapy for pain management with FDA approval and our launch of Mitigo," Piramal Critical Care CEO Peter DeYoung said.
Piramal Critical Care has established itself as the leader in US intrathecal therapy with Gablofen which it has successfully integrated post acquisition from Mallinckrodt, he added.
It is a business division of Piramal Enterprises and present in anesthesia, pain management, and intrathecal therapy segments.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app